Residual symptoms in depressed patients who respond acutely to fluoxetine

Andrew A. Nierenberg, Bronwyn R. Keefe, Vinita C. Leslie, Jonathan E. Alpert, Joel A. Pava, John J. Worthington, Jerrold F. Rosenbaum, Maurizio Fava

Research output: Contribution to journalArticle

372 Citations (Scopus)

Abstract

Background: Antidepressants have unequivocal efficacy as compared with placebo, but many patients have residual symptoms despite a robust response to antidepressant therapy. The purpose of this study is to assess residual symptoms in outpatients who respond acutely to fluoxetine. Method: Two hundred and fifteen outpatients with major depressive disorder as assessed with the Structured Clinical Interview for DSM-III-R (SCID-P) were treated openly with fluoxetine 20 mg/day for 8 weeks. One hundred and eight (50.2%) were considered full responders (final 17-item Hamilton Rating Scale for Depression [HAM-D] score ≤7). Percentages of full responders who continued to have subthreshold or full major depressive disorder symptoms were calculated. The relationship between residual symptoms and Axis I and Axis II (assessed with SCID-II for personality disorders) comorbidity was assessed. Results: Of the 108 responders, 19 (17.6%) had no subthreshold or threshold SCID-P major depressive disorder symptoms, while 28 (25.9%) had 1 symptom, and 61 (56.5%) had 2 or more symptoms. No statistically significant relationships were found between number of residual symptoms and selected Axis I comorbid conditions or total number of Axis II disorders. Conclusion: Less than 20% of full responders to fluoxetine by HAM-D criteria were free of all SCID-P subthreshold and threshold major depressive disorder symptoms after 8 weeks of treatment. While depressed patients benefit from antidepressants, most continue to have some symptoms of depression. The high prevalence of residual symptoms among antidepressant responders suggests the need for further study including whether residual symptoms abate with longer treatment or increased dose of fluoxetine. Other strategies, such as cognitive behavioral therapy, may be needed to address residual symptoms.

Original languageEnglish (US)
Pages (from-to)221-225
Number of pages5
JournalJournal of Clinical Psychiatry
Volume60
Issue number4
StatePublished - Apr 1999
Externally publishedYes

Fingerprint

Fluoxetine
Major Depressive Disorder
Antidepressive Agents
Depression
Outpatients
Personality Disorders
Cognitive Therapy
Diagnostic and Statistical Manual of Mental Disorders
Comorbidity
Therapeutics
Placebos
Interviews

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., ... Fava, M. (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry, 60(4), 221-225.

Residual symptoms in depressed patients who respond acutely to fluoxetine. / Nierenberg, Andrew A.; Keefe, Bronwyn R.; Leslie, Vinita C.; Alpert, Jonathan E.; Pava, Joel A.; Worthington, John J.; Rosenbaum, Jerrold F.; Fava, Maurizio.

In: Journal of Clinical Psychiatry, Vol. 60, No. 4, 04.1999, p. 221-225.

Research output: Contribution to journalArticle

Nierenberg, AA, Keefe, BR, Leslie, VC, Alpert, JE, Pava, JA, Worthington, JJ, Rosenbaum, JF & Fava, M 1999, 'Residual symptoms in depressed patients who respond acutely to fluoxetine', Journal of Clinical Psychiatry, vol. 60, no. 4, pp. 221-225.
Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry. 1999 Apr;60(4):221-225.
Nierenberg, Andrew A. ; Keefe, Bronwyn R. ; Leslie, Vinita C. ; Alpert, Jonathan E. ; Pava, Joel A. ; Worthington, John J. ; Rosenbaum, Jerrold F. ; Fava, Maurizio. / Residual symptoms in depressed patients who respond acutely to fluoxetine. In: Journal of Clinical Psychiatry. 1999 ; Vol. 60, No. 4. pp. 221-225.
@article{b1c8e1569bb543279046f889a49cbfd0,
title = "Residual symptoms in depressed patients who respond acutely to fluoxetine",
abstract = "Background: Antidepressants have unequivocal efficacy as compared with placebo, but many patients have residual symptoms despite a robust response to antidepressant therapy. The purpose of this study is to assess residual symptoms in outpatients who respond acutely to fluoxetine. Method: Two hundred and fifteen outpatients with major depressive disorder as assessed with the Structured Clinical Interview for DSM-III-R (SCID-P) were treated openly with fluoxetine 20 mg/day for 8 weeks. One hundred and eight (50.2{\%}) were considered full responders (final 17-item Hamilton Rating Scale for Depression [HAM-D] score ≤7). Percentages of full responders who continued to have subthreshold or full major depressive disorder symptoms were calculated. The relationship between residual symptoms and Axis I and Axis II (assessed with SCID-II for personality disorders) comorbidity was assessed. Results: Of the 108 responders, 19 (17.6{\%}) had no subthreshold or threshold SCID-P major depressive disorder symptoms, while 28 (25.9{\%}) had 1 symptom, and 61 (56.5{\%}) had 2 or more symptoms. No statistically significant relationships were found between number of residual symptoms and selected Axis I comorbid conditions or total number of Axis II disorders. Conclusion: Less than 20{\%} of full responders to fluoxetine by HAM-D criteria were free of all SCID-P subthreshold and threshold major depressive disorder symptoms after 8 weeks of treatment. While depressed patients benefit from antidepressants, most continue to have some symptoms of depression. The high prevalence of residual symptoms among antidepressant responders suggests the need for further study including whether residual symptoms abate with longer treatment or increased dose of fluoxetine. Other strategies, such as cognitive behavioral therapy, may be needed to address residual symptoms.",
author = "Nierenberg, {Andrew A.} and Keefe, {Bronwyn R.} and Leslie, {Vinita C.} and Alpert, {Jonathan E.} and Pava, {Joel A.} and Worthington, {John J.} and Rosenbaum, {Jerrold F.} and Maurizio Fava",
year = "1999",
month = "4",
language = "English (US)",
volume = "60",
pages = "221--225",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Residual symptoms in depressed patients who respond acutely to fluoxetine

AU - Nierenberg, Andrew A.

AU - Keefe, Bronwyn R.

AU - Leslie, Vinita C.

AU - Alpert, Jonathan E.

AU - Pava, Joel A.

AU - Worthington, John J.

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

PY - 1999/4

Y1 - 1999/4

N2 - Background: Antidepressants have unequivocal efficacy as compared with placebo, but many patients have residual symptoms despite a robust response to antidepressant therapy. The purpose of this study is to assess residual symptoms in outpatients who respond acutely to fluoxetine. Method: Two hundred and fifteen outpatients with major depressive disorder as assessed with the Structured Clinical Interview for DSM-III-R (SCID-P) were treated openly with fluoxetine 20 mg/day for 8 weeks. One hundred and eight (50.2%) were considered full responders (final 17-item Hamilton Rating Scale for Depression [HAM-D] score ≤7). Percentages of full responders who continued to have subthreshold or full major depressive disorder symptoms were calculated. The relationship between residual symptoms and Axis I and Axis II (assessed with SCID-II for personality disorders) comorbidity was assessed. Results: Of the 108 responders, 19 (17.6%) had no subthreshold or threshold SCID-P major depressive disorder symptoms, while 28 (25.9%) had 1 symptom, and 61 (56.5%) had 2 or more symptoms. No statistically significant relationships were found between number of residual symptoms and selected Axis I comorbid conditions or total number of Axis II disorders. Conclusion: Less than 20% of full responders to fluoxetine by HAM-D criteria were free of all SCID-P subthreshold and threshold major depressive disorder symptoms after 8 weeks of treatment. While depressed patients benefit from antidepressants, most continue to have some symptoms of depression. The high prevalence of residual symptoms among antidepressant responders suggests the need for further study including whether residual symptoms abate with longer treatment or increased dose of fluoxetine. Other strategies, such as cognitive behavioral therapy, may be needed to address residual symptoms.

AB - Background: Antidepressants have unequivocal efficacy as compared with placebo, but many patients have residual symptoms despite a robust response to antidepressant therapy. The purpose of this study is to assess residual symptoms in outpatients who respond acutely to fluoxetine. Method: Two hundred and fifteen outpatients with major depressive disorder as assessed with the Structured Clinical Interview for DSM-III-R (SCID-P) were treated openly with fluoxetine 20 mg/day for 8 weeks. One hundred and eight (50.2%) were considered full responders (final 17-item Hamilton Rating Scale for Depression [HAM-D] score ≤7). Percentages of full responders who continued to have subthreshold or full major depressive disorder symptoms were calculated. The relationship between residual symptoms and Axis I and Axis II (assessed with SCID-II for personality disorders) comorbidity was assessed. Results: Of the 108 responders, 19 (17.6%) had no subthreshold or threshold SCID-P major depressive disorder symptoms, while 28 (25.9%) had 1 symptom, and 61 (56.5%) had 2 or more symptoms. No statistically significant relationships were found between number of residual symptoms and selected Axis I comorbid conditions or total number of Axis II disorders. Conclusion: Less than 20% of full responders to fluoxetine by HAM-D criteria were free of all SCID-P subthreshold and threshold major depressive disorder symptoms after 8 weeks of treatment. While depressed patients benefit from antidepressants, most continue to have some symptoms of depression. The high prevalence of residual symptoms among antidepressant responders suggests the need for further study including whether residual symptoms abate with longer treatment or increased dose of fluoxetine. Other strategies, such as cognitive behavioral therapy, may be needed to address residual symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0032908414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032908414&partnerID=8YFLogxK

M3 - Article

C2 - 10221281

AN - SCOPUS:0032908414

VL - 60

SP - 221

EP - 225

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -